ISIS #

Related by string. * ISi . Isis . Isi . isi . ISID . iSi . iSIS . isis : Avid Unity ISIS . DG ISI . CrossRef ISI Medline . FULL TEXT ISI PUBMED . ISI Medline . CrossRef ISI . ISIS Papyrus . ISIS . Isis Pharmaceuticals Inc. / # [012] . # [007] . # [016] . #s [002] . # [014] . #s [004] . # [004] . # [022] : #.# ov #-# . ID # # . #-#:# pm [001] . i Newswire #-#-# . Call #-#-# [002] . #-#-# ATS [003] . #-#-# ATS [002] . +#-#-#-# [004] * *

Related by context. All words. (Click for frequent words.) 74 Mipomersen 73 PRTX 72 INCB# [001] 72 PS# [001] 72 mipomersen 71 lomitapide 71 Symadex 71 eprotirome 71 R#/MEM # 70 ganetespib 70 metaglidasen 70 AEGR 70 CR# vcMMAE 70 PSN# [002] 69 HQK 69 LY# [003] 69 oral prodrug 69 OXi# 69 SRT# [003] 69 enzastaurin 69 RDEA# 69 BAY #-# 69 orally bioavailable 69 Tyrima 68 selective androgen receptor modulator 68 urocortin 2 68 MYDICAR ® 68 teriflunomide 68 Dapagliflozin 68 CRLX# 68 HuMax EGFr 68 PEG SN# 68 JAK inhibitor 68 elotuzumab 68 MEK inhibitor 68 Epanova 68 RGB # 68 AEG# 68 XmAb# 68 Carfilzomib 68 Triolex 68 phase IIb clinical 68 forodesine 68 RLY# 68 teplizumab 68 PEG PAL 68 Phenoptin 68 glucokinase activator 68 phase IIa clinical 68 INCB# [002] 68 PRT# 68 HuLuc# 68 atacicept 67 ENMD # 67 ularitide 67 Bicifadine 67 CRx 67 PXD# 67 Azedra 67 alvespimycin 67 CA4P 67 Sym# 67 6R BH4 67 favorable pharmacokinetic profile 67 ARRY 67 CIMZIA TM 67 LymphoStat B 67 ataluren 67 Pimavanserin 67 rNAPc2 67 INT# [002] 67 Archexin 67 cediranib 67 alagebrium 67 Bezielle 67 TRO# 67 TBC# 67 MYDICAR 67 PEG Interferon lambda 67 ALTU 67 Nasulin 67 CCX# 67 CIMZIA ™ 67 DCCR 66 TRV# [001] 66 pertuzumab 66 CTAP# Capsules 66 MDV# 66 tanespimycin 66 teduglutide 66 Zerenex 66 PHX# 66 YONDELIS 66 Phase 2a trial 66 BCX# 66 axitinib 66 liposomal formulation 66 CORT # 66 Xanafide 66 mertansine 66 daclizumab 66 Plicera 66 LAF# 66 refractory gout 66 GFT# 66 Virulizin ® 66 Amrubicin 66 ATL# [001] 66 Phase 2a 66 ELACYT 66 brivaracetam 66 ELND# 66 HGS# 66 ruboxistaurin 66 CYT# 66 pan HDAC inhibitor 66 MLN# 66 Panzem R 66 TACI Ig 66 insulin sensitizing 66 Tezampanel 66 ATL/TV# 66 CoFactor 66 NGX# 66 Phase Ib study 66 MGCD# [001] 66 tolerability profile 66 AEZS 66 Phase 1b trial 66 Genz # 66 atrasentan 66 phase IIb trial 66 danoprevir 66 Targretin 65 riociguat 65 pharmacokinetic PK profile 65 Chemophase 65 ProSavin 65 Traficet EN 65 HGS ETR1 65 uricase 65 Phase 2a clinical 65 pomalidomide 65 TRIOLEX 65 TG# [003] 65 diabetic neuropathic pain 65 Phase 1b 65 otelixizumab 65 placebo controlled Phase 65 Phase IIa clinical 65 orally administered inhibitor 65 PDE4 inhibitor 65 Phase IIa 65 MEK inhibitors 65 Iloperidone 65 INCB# [003] 65 HoFH 65 Saxagliptin 65 Phase IIa trials 65 rFIXFc 65 KNS # 65 tezampanel 65 Dasatinib 65 HCV protease inhibitor 65 neratinib 65 phase IIb 65 Androxal TM 65 dirucotide 65 PRX # 65 Phase Ib 65 APD# 65 huC# DM4 65 CBLC# 65 Naproxcinod 65 Bortezomib 65 pharmacokinetic PK 65 muraglitazar 65 celgosivir 65 angiogenesis inhibitor 65 Guanilib 65 sodium glucose cotransporter 65 eltrombopag 65 glufosfamide 65 obatoclax 65 Aplidin 65 ORMD 65 Phase 2b clinical trials 65 GLYX 65 phase 2a 65 anti amnesic 65 preclinical efficacy 65 preclinically 65 sunitinib malate 65 AZILECT R 65 gefitinib Iressa 65 FTY# 65 tolvaptan 65 angiotensin receptor blocker ARB 65 antisense drug 65 serum phosphate 65 hypercholesterolemia 65 MAP# 65 elagolix 65 OHR/AVR# 65 VAPRISOL 65 HuMax CD# 64 HuMax CD4 64 selective modulator 64 Serdaxin 64 Annamycin 64 Alocrest 64 corticosteroid dexamethasone 64 Ostarine 64 fluvastatin 64 HGS ETR2 64 APOPTONE 64 pramlintide 64 APTIVUS 64 RAPAFLO 64 GAMMAGARD 64 C1 INH 64 Omacetaxine 64 ADX# 64 anticancer compound 64 IMA# 64 ZOLINZA 64 latrepirdine 64 VA# [002] 64 Phase Ib clinical 64 Aurexis 64 JAK2 inhibitor 64 Lixivaptan 64 cilengitide 64 Debio 64 TELINTRA 64 Nanobody 64 JAK inhibitors 64 TriRima 64 neuroprotective properties 64 orally dosed 64 thymalfasin 64 KRN# 64 VEGF Trap 64 Cloretazine R VNP#M 64 IL# PE#QQR 64 ApoB SNALP 64 fostamatinib 64 lintuzumab 64 LY# [002] 64 nalbuphine ER 64 glucagon receptor 64 vidofludimus 64 Aflibercept 64 laquinimod 64 visilizumab 64 ocrelizumab 64 Aurora kinase 64 trodusquemine 64 pharmacodynamic effects 64 decitabine 64 ANAVEX #-# [003] 64 TKM ApoB 64 cannabinor 64 EOquin TM 64 Amplimexon 64 ZYBRESTAT 64 Asentar 64 Ocrelizumab 64 Posiphen 64 Phase #b/#a 64 IDX# 64 PF # [001] 64 IRX 2 64 SPC# [001] 64 safinamide 64 evaluating tivozanib 64 AVN# [001] 64 Lisofylline 64 #ME# 64 darapladib 64 perifosine 64 cMET 64 Ophena TM 64 PCK# 64 RhuDex 64 primary hypercholesterolemia 64 CEQ# 64 proteasome inhibitor 64 GRN#L 64 ALN PCS 64 Corlux 64 aleglitazar 64 Vidofludimus 64 IFN α 64 torezolid phosphate 64 PROMACTA 64 Phase 2b trial 64 lixisenatide 64 pharmacodynamic profile 64 GALNS 64 INGN 64 Squalamine 64 Factor VIIa 64 mapatumumab 63 favorable tolerability 63 Perifosine 63 SERMs 63 lumiliximab 63 insulin degludec 63 BAL# [002] 63 dacetuzumab 63 talactoferrin 63 NKTR 63 davunetide intranasal AL 63 INTEGRILIN 63 QNEXA 63 AMR# 63 denufosol 63 EndoTAG TM -1 63 docetaxel Taxotere R 63 Panzem 63 antisense inhibitors 63 Marqibo 63 anti leukemic 63 Cinquil 63 homozygous familial hypercholesterolemia 63 standard chemotherapy regimen 63 ThGRF 63 vorinostat 63 CD# antibody [001] 63 ALKS 63 Phase Ia 63 Liraglutide 63 entinostat 63 QLT# 63 SLx 63 sitaxsentan 63 olmesartan 63 MAXY G# 63 DAVANAT 63 imetelstat 63 Telcyta 63 reslizumab 63 Amigal 63 pegylated interferons 63 Pioglitazone 63 metformin sulfonylurea 63 Lu AA# 63 DDP# 63 mixed dyslipidemia 63 Candesartan 63 Varespladib 63 Phase 2b study 63 SCH # 63 pitavastatin 63 lixivaptan 63 anticancer agent 63 Nanobody ® 63 elesclomol 63 GW# [003] 63 tasocitinib 63 Relivar 63 mixed hyperlipidemia 63 vascular disrupting agents 63 RG# [001] 63 delafloxacin 63 liprotamase 63 investigational compound 63 selective agonist 63 Glufosfamide 63 BZL# 63 CCR9 antagonist 63 SGLT2 63 lupus nephritis 63 GSK# [001] 63 XL# XL# XL# XL# 63 oral bioavailability 63 Aliskiren 63 LibiGel ® 63 canakinumab 63 urate lowering 63 Fibrillex TM 63 phase IIa 63 glucose lowering 63 tolerability profiles 63 Enzastaurin 63 Muraglitazar 63 zileuton 63 sargramostim 63 TPI ASM8 63 mGluR5 NAM 63 sapacitabine 63 Phase IIa trial 63 dimebon 63 Cloretazine ® 63 Icatibant 63 AP# [003] 63 PSMA ADC 63 Technosphere Insulin 63 Lp PLA 2 63 Golimumab 63 USL# 63 Phase 2b 63 colesevelam HCl 63 Neulasta ® 63 DU #b 63 HCV protease 63 deforolimus 63 LCP Tacro 63 Cloretazine 63 HMG CoA reductase inhibitors 63 eniluracil 63 bardoxolone 63 Randomized Phase 63 XL# [003] 63 Darusentan 63 TH# [003] 63 HCD# [002] 63 aripiprazole Abilify 63 PSN# [001] 63 ATACAND 63 AZD# 63 eculizumab 63 prucalopride 63 Oral NKTR 63 PLK1 SNALP 63 JAK1 63 Opexa 63 Pertuzumab 63 BNC# 63 Ambrisentan 63 insulin sensitizers 63 Vicriviroc 63 Vilazodone 63 Rosuvastatin 63 seliciclib 63 AMD# [003] 63 tafamidis 63 Alpharadin 63 generation antisense inhibitor 63 Vaprisol 63 histone deacetylase inhibitor 63 phase IIb study 63 carfilzomib 63 cobiprostone 63 zanolimumab 63 Imprime PGG 63 MERLIN TIMI 63 ONCONASE R 63 Rebif ® 63 fosbretabulin 63 IMC A# 63 omecamtiv mecarbil 63 NLX P# 62 relapsed multiple myeloma 62 Ostabolin C 62 ASONEP 62 DXL# 62 amrubicin 62 Panzem R NCD 62 varespladib 62 Blinatumomab 62 MetMAb 62 lesinurad 62 somatostatin analogue 62 vascular disrupting agent 62 CD NP 62 insulin sensitizer 62 alvimopan 62 Vandetanib 62 velafermin 62 Tanespimycin 62 viral kinetic 62 hyperphenylalaninemia HPA due 62 Cetrorelix 62 SPP# [001] 62 AQ4N 62 Exelixis XL# 62 CD# monoclonal antibody 62 pradefovir 62 squalamine 62 diabetic nephropathy 62 Viprinex 62 fenofibric acid 62 CDP# 62 triglyceride lowering 62 rilonacept 62 RSD# 62 aplindore 62 Tarceva TM 62 Neurodex 62 Troxatyl 62 investigational humanized monoclonal antibody 62 IAP inhibitors 62 Locteron 62 methylnaltrexone 62 DB# [003] 62 uric acid lowering 62 Rasilez Tekturna 62 Teriflunomide 62 Atiprimod 62 Onconase 62 Phase #/#a trial 62 ponatinib 62 Capesaris 62 GRN# 62 radezolid 62 Phase 2b clinical 62 GRNCM1 62 Aclidinium 62 SARMs 62 bafetinib 62 Eltrombopag 62 veltuzumab 62 Phase Ib II 62 Locteron ® 62 Safinamide 62 ACZ# 62 Ozarelix 62 novel VDA molecule 62 EOquin 62 NATRECOR R 62 pharmacokinetic PK study 62 nucleoside analog 62 Phase 1a clinical 62 preclinical studies 62 Degludec 62 postoperative ileus 62 XL# XL# XL# 62 Ceflatonin R 62 trastuzumab Herceptin 62 MAGE A3 ASCI 62 ISTODAX 62 dose escalation Phase 62 Phase IIB 62 preclinical 62 tarenflurbil 62 parathyroid hormone PTH 62 PREOS 62 erlotinib Tarceva ® 62 Chrysalin 62 ascending dose 62 Desmoteplase 62 midstage clinical 62 humanized anti 62 davalintide 62 NXL# 62 TRAIL receptor antibodies 62 Nuvion 62 Trofex 62 vosaroxin 62 MB# [004] 62 Aegerion 62 renin inhibitors 62 Arikace 62 ASA# 62 calcitonin 62 belinostat 62 mGluR5 negative 62 Abiraterone acetate 62 Arcalyst 62 APEX PD 62 TREDAPTIVE 62 DFMO 62 anti CD3 antibody 62 OMP #M# 62 octreotide acetate 62 ORENCIA R 62 sorafenib Nexavar 62 iniparib 62 maximally tolerated dose 62 NOX E# 62 Virulizin R 62 eosinophilic asthma 62 ulimorelin 62 ULORIC 62 Leukine 62 DPP4 inhibitor 62 Hsp# inhibitor 62 PBT2 62 AVONEX ® 62 EVIZON 62 systemically administered 62 TREANDA 62 Valsartan 62 LCP AtorFen 62 pharmacokinetic properties 62 ancrod 62 Cethrin 62 investigational compounds 62 arzoxifene 62 Fx #A 62 voreloxin 62 Alzhemed TM 62 Denufosol 62 GSK# [002] 62 RNAi therapeutic targeting PCSK9 62 Fabry Disease 62 tiapamil 62 Trastuzumab 62 Elotuzumab 62 pioglitazone HCl 62 tubulin inhibitor 62 PARP inhibitor 62 dose cohorts 62 OncoVEX GM CSF 62 regorafenib 62 Zybrestat 62 Vitaxin 62 bifeprunox 62 ICA # 62 selective inhibition 62 CD# CEA 62 mGluR2 NAM 62 investigational drug 62 elacytarabine 62 CGEN # 62 CYT# potent vascular disrupting 62 inhibitor RG# 62 therapeutic monoclonal antibody 62 epigenetic therapies 62 posaconazole 62 PD LID 62 Dacogen injection 62 telomerase therapeutic 62 pharmacodynamic properties 62 XYOTAX TM 62 nitazoxanide 62 BiTE antibodies 62 Menerba 62 GLPG# 62 AZILECT ® 62 ostarine 61 VEGF receptor 61 preclinical pharmacokinetic 61 cangrelor 61 Tasimelteon 61 non nucleoside inhibitor 61 MEK inhibitor RDEA# 61 leukemia AML 61 synthetic retinoid 61 Laquinimod 61 pharmacodynamic PD 61 JANUVIA 61 Daclizumab 61 TNF Tumor Necrosis Factor 61 rFVIIIFc 61 Ceflatonin 61 Inhalation Solution 61 IPL# 61 ALN HPN 61 Myocet 61 FOLOTYN ® 61 bosentan 61 pharmacodynamic 61 Phase IIIb clinical 61 aflibercept 61 NeuVax 61 MGCD# [002] 61 PDX pralatrexate 61 MKC# MKC# PP 61 tipifarnib 61 Tarvacin 61 rHuPH# 61 Tolvaptan 61 odanacatib 61 Uricase PEG 61 CINOD 61 acyclovir Lauriad R 61 pharmacokinetic profile 61 darusentan 61 Atrasentan 61 dexpramipexole 61 Phase 2b Clinical Trial 61 efaproxiral 61 Exherin TM 61 Maribavir 61 elevated LDL cholesterol 61 phase Ib 61 ALN VSP 61 LIVALO 61 nebivolol 61 ALN TTR 61 protein kinase inhibitor 61 Nexavar sorafenib 61 CINQUIL 61 Affinitak 61 Androxal 61 clinical pharmacology studies 61 rALLy 61 KB# [002] 61 Adalimumab 61 AeroLEF TM 61 EnzymeRx 61 Actilon 61 REGN# 61 Bendavia 61 candesartan cilexetil 61 antitumor effects 61 Tesetaxel 61 terlipressin 61 renin inhibitor 61 teriparatide 61 NNR Therapeutics 61 tocilizumab 61 ONTAK 61 HspE7 61 PDE4 inhibitors 61 tolerability 61 MTP inhibitor 61 Voreloxin 61 UPLYSO 61 immune modulating 61 SYN# 61 relapsed MM 61 Sapacitabine 61 Urocortin 2 61 vildagliptin 61 virus HCV protease inhibitor 61 Preclinical studies suggest 61 cancer cachexia 61 beta 1a 61 Pharmacokinetic PK 61 LT NS# 61 oral ridaforolimus 61 Clolar ® 61 Diamyd ® 61 Tamibarotene 61 Cysteamine 61 Epratuzumab 61 Zoraxel 61 QuatRx 61 Milnacipran 61 adipiplon 61 indibulin 61 Proellex TM 61 ALGRX 61 #mg dose [001] 61 investigational hepatitis C 61 ALD# 61 antidiabetic 61 TELCYTA 61 Elagolix 61 Pazopanib 61 Thiarabine 61 familial hypercholesterolemia FH 61 olaparib 61 Rasagiline 61 bortezomib Velcade 61 Olmesartan 61 Topiramate 61 antibody MAb 61 cariprazine 61 multicenter Phase II 61 ESBA# 61 Azedra TM 61 TYZEKA 61 CIMZIA TM certolizumab pegol 61 tramiprosate Alzhemed TM 61 Avanafil 61 oral antiviral 61 galiximab 61 antiangiogenic 61 ALB # 61 telcagepant 61 Gabapentin GR 61 iSONEP 61 ACTEMRA TM 61 GPx 61 Phase 2a Clinical Trial 61 CERE 61 CUDC 61 Exelixis compounds 61 neurogenic orthostatic hypotension 61 R roscovitine 61 ACAPODENE 61 ranolazine 61 Enzyme Replacement Therapy 61 Quinamed 61 Boceprevir 61 PKC# 61 Panitumumab 61 Albugon 61 Huntexil 61 erlotinib Tarceva 61 volociximab 61 Catena ® 61 DAPT 61 Clonicel 61 enoximone 61 RAV# 61 Regeneron Pharma 61 Hsp# inhibitors 61 receptor inhibitor 61 XL# XL# 61 ambrisentan 61 ALN TTR# 61 microplasmin 61 SAR# [004] 61 CYCLOSET 61 Perforomist ™ Inhalation Solution 61 Allovectin 7 R 61 lipid lowering therapies 61 #D#C# 61 inhaled formulation 61 Zoledronic acid 61 histone deacetylase HDAC inhibitor 61 GKAs 61 Peginterferon 61 Navelbine ® 61 Æterna Zentaris 61 Rotigotine 61 bicifadine 61 targeted radiotherapeutic 61 Genasense R oblimersen 61 Anacetrapib 61 bendamustine 61 MultiStem 61 Personalized Immunotherapy 61 TOCOSOL Paclitaxel 61 Trizytek 61 JP-#/fipamezole 61 INC# 61 RhuDex ® 61 OMP #R# 61 TASKi2 61 Phase #b/#a trial 61 selective kinase inhibitor 61 antithrombotic 61 perampanel 61 lintuzumab SGN 61 investigational monoclonal antibody 61 MBP# [001] 61 Tumor Necrosis Factor 61 ritonavir boosted 61 velafermin belinostat 61 Syncria 61 inecalcitol 61 myeloproliferative disorders 61 THR beta agonist 61 Ventavis 61 Prestara 61 NexACT 61 E2F Decoy 61 HCV protease inhibitors 61 midstage trials 60 paclitaxel Taxol 60 Lisofylline LSF 60 Phase IIb clinical trials 60 CCR2 60 albiglutide 60 CORLUX 60 favorable pharmacokinetic 60 pharmacokinetic 60 Natalizumab 60 Meets Primary Endpoint 60 NU# [001] 60 ruxolitinib 60 masitinib 60 muscarinic 60 ANG# 60 Pharmacokinetic 60 dose cohort 60 receptor agonists 60 active comparator 60 epothilones 60 JAK3 60 HER2 positive metastatic breast 60 TOLAMBA 60 Vidaza azacitidine 60 LibiGel Phase III 60 sodium glucose transporter 60 CANCIDAS 60 Adlea 60 CaPre TM 60 proteasome inhibitors 60 Tekamlo 60 oral FTY# 60 ONGLYZA ™ 60 ALVESCO HFA 60 mTOR inhibitor 60 rosuvastatin Crestor 60 compound INCB# 60 vicriviroc 60 fenretinide 60 calcitriol 60 JAK Inhibitor 60 Linaclotide 60 nucleoside 60 adecatumumab 60 BENLYSTA ® 60 ceftazidime 60 CDK inhibitor 60 rindopepimut 60 exenatide 60 Phase IIb clinical 60 Miraxion 60 thalidomide Thalomid 60 solithromycin 60 Oxypurinol 60 AVE# 60 Olaparib 60 Synavive 60 Darapladib 60 FLT3 60 pharmacokinetic pharmacodynamic 60 demonstrated antitumor activity 60 romiplostim 60 ABILIFY ® 60 sorafenib tablets 60 subcutaneously administered 60 Phase IIb Trial 60 aflibercept VEGF Trap 60 Bronchitol 60 NN# [001] 60 PTH analogue 60 immunomodulating 60 romidepsin 60 polymerase inhibitor 60 investigational oral 60 antifibrotic 60 AERx iDMS 60 coadministration 60 Revlimid lenalidomide 60 pegloticase 60 orBec 60 metreleptin 60 S/GSK# 60 Dalbavancin 60 dyskinesia PD LID 60 administered subcutaneously 60 Tavocept 60 XL# SAR# 60 OX1 60 PEGylated 60 aclidinium 60 sitagliptin 60 Exenatide 60 Febuxostat 60 Telmisartan 60 alpha 2a 60 Phase III ALLEGRO 60 A3 adenosine receptor 60 Viprinex TM 60 oral picoplatin 60 tezampanel NGX# 60 partial agonist 60 Benlysta belimumab 60 lapatinib Tykerb 60 relapsed refractory multiple myeloma 60 Cimzia R 60 OMNARIS HFA 60 PROSTVAC TM 60 Valdoxan 60 HZT 60 nab paclitaxel 60 cardioprotective effects 60 LymphoStat B TM 60 leading oral taxane 60 ZD# [001] 60 antiangiogenic activity 60 pharmacokinetics PK 60 ADAGIO study 60 insulin analogs 60 hA# 60 pharmacokinetic interactions 60 Cotara 60 TRISENOX 60 Antitumor Activity 60 aliskiren 60 albinterferon alfa 2b 60 triphendiol 60 2 methoxyestradiol 60 BRAF inhibitor 60 vinca alkaloid 60 PEGPH# 60 LDL cholesterol lowering 60 RG# ITMN 60 adalimumab Humira 60 safety tolerability pharmacokinetic 60 intranasal formulation 60 Fibrillex 60 abiraterone 60 oral antidiabetic 60 registrational trial 60 allosteric modulator 60 Zemplar Capsules 60 cathepsin K inhibitor 60 clevidipine 60 Reverset 60 thiazolidinediones TZDs 60 lanthanum carbonate 60 Microplasmin 60 generation antisense 60 omacetaxine 60 ciclesonide 60 Numax 60 CCR9 60 LUX Lung

Back to home page